These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
258 related articles for article (PubMed ID: 35169086)
1. [Perspectives on Precision Medicine in Primary Central Nervous System Lymphoma]. Sasaki N; Nagane M No Shinkei Geka; 2022 Jan; 50(1):51-60. PubMed ID: 35169086 [TBL] [Abstract][Full Text] [Related]
2. [Molecular pathogenesis and therapeutic development of primary central nervous system lymphoma: update and future perspectives]. Nagane M Rinsho Ketsueki; 2022; 63(9):1145-1156. PubMed ID: 36198540 [TBL] [Abstract][Full Text] [Related]
3. Lymphomas of Central Nervous System. Yokogami K; Azuma M; Takeshima H; Hirai T Adv Exp Med Biol; 2023; 1405():527-543. PubMed ID: 37452952 [TBL] [Abstract][Full Text] [Related]
4. CD79B Y196 mutation is a potent predictive marker for favorable response to R-MPV in primary central nervous system lymphoma. Yamaguchi J; Ohka F; Lushun C; Motomura K; Aoki K; Takeuchi K; Nagata Y; Ito S; Mizutani N; Ohno M; Suzaki N; Takasu S; Seki Y; Kano T; Wakabayashi K; Oyama H; Kurahashi S; Tanahashi K; Hirano M; Shimizu H; Kitano Y; Maeda S; Yamazaki S; Wakabayashi T; Kondo Y; Natsume A; Saito R Cancer Med; 2023 Mar; 12(6):7116-7126. PubMed ID: 36478416 [TBL] [Abstract][Full Text] [Related]
5. Bruton's Tyrosine Kinase Inhibitors in Refractory or Relapsing Primary Central Nervous System Lymphoma: A Meta-analysis and Systematic Review. Guo HP; Dang XL; Kang L; Liu C; Liu XW World Neurosurg; 2024 Aug; 188():161-169. PubMed ID: 38641241 [TBL] [Abstract][Full Text] [Related]
6. Bruton's tyrosine kinase (BTK) inhibitors for the treatment of primary central nervous system lymphoma (PCNSL): current progress and latest advances. Schaff L; Nayak L; Grommes C Leuk Lymphoma; 2024 Jul; 65(7):882-894. PubMed ID: 38597202 [TBL] [Abstract][Full Text] [Related]
7. Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma. Steffanoni S; Batchelor TT Curr Opin Neurol; 2021 Dec; 34(6):848-856. PubMed ID: 34581302 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of Primary Central Nervous System Lymphoma: Standard Treatments According to the Japanese 2019 Guideline and Novel Treatments]. Sasaki N; Nagane M Brain Nerve; 2021 Oct; 73(10):1107-1114. PubMed ID: 34615748 [TBL] [Abstract][Full Text] [Related]
9. Primary central nervous system lymphoma: Novel precision therapies. Mondello P; Mian M; Bertoni F Crit Rev Oncol Hematol; 2019 Sep; 141():139-145. PubMed ID: 31295667 [TBL] [Abstract][Full Text] [Related]
10. Phase I/II study of tirabrutinib, a second-generation Bruton's tyrosine kinase inhibitor, in relapsed/refractory primary central nervous system lymphoma. Narita Y; Nagane M; Mishima K; Terui Y; Arakawa Y; Yonezawa H; Asai K; Fukuhara N; Sugiyama K; Shinojima N; Kitagawa J; Aoi A; Nishikawa R Neuro Oncol; 2021 Jan; 23(1):122-133. PubMed ID: 32583848 [TBL] [Abstract][Full Text] [Related]
11. Primary central nervous system lymphoma. Schaff LR; Grommes C Blood; 2022 Sep; 140(9):971-979. PubMed ID: 34699590 [TBL] [Abstract][Full Text] [Related]
13. Bruton's tyrosine kinase inhibitors in primary central nervous system lymphoma-evaluation of anti-tumor efficacy and brain distribution. Yu H; Kong H; Li C; Dong X; Wu Y; Zhuang Y; Han S; Lei T; Yang H Transl Cancer Res; 2021 May; 10(5):1975-1983. PubMed ID: 35116520 [TBL] [Abstract][Full Text] [Related]
14. Diffuse large B-cell lymphoma involving the central nervous system: biologic rationale for targeted therapy. Roschewski M; Hodson DJ Haematologica; 2024 Feb; 109(2):388-400. PubMed ID: 37706315 [TBL] [Abstract][Full Text] [Related]
15. Naquotinib exerts antitumor activity in activated B-cell-like diffuse large B-cell lymphoma. Tanaka H; Kaneko N; Sakagami H; Matsuya T; Hiramoto M; Yamanaka Y; Mori M; Koshio H; Hirano M; Takeuchi M Leuk Res; 2020 Jan; 88():106286. PubMed ID: 31865062 [TBL] [Abstract][Full Text] [Related]
17. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study. Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202 [TBL] [Abstract][Full Text] [Related]
18. Long-term Complete Remission of Decitabine-Primed Tandem CD19/CD22 CAR-T Therapy with PD-1 and BTK Inhibitors Maintenance in a Refractory Primary Central Nervous System Lymphoma Patient. Zou R; Zhou X; Liu H; Wang P; Xia F; Kang L; Yu L; Wu D; Jin Z; Qu C Cancer Res Treat; 2023 Oct; 55(4):1363-1368. PubMed ID: 37321275 [TBL] [Abstract][Full Text] [Related]
19. Treatment of Primary Central Nervous System Lymphoma: From Chemotherapy to Small Molecules. Mendez JS; Grommes C Am Soc Clin Oncol Educ Book; 2018 May; 38():604-615. PubMed ID: 30231317 [TBL] [Abstract][Full Text] [Related]
20. Activity of ibrutinib plus R-CHOP in diffuse large B-cell lymphoma: Response, pharmacodynamic, and biomarker analyses of a phase Ib study. Schaffer M; Chaturvedi S; Davis C; de Jong J; Aquino R; Oki Y; Fourneau N; Younes A; Balasubramanian S Cancer Treat Res Commun; 2020; 25():100235. PubMed ID: 33188997 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]